N Andreasen

Summary

Affiliation: Sunderby Hospital
Country: Sweden

Publications

  1. pmc Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    J Neurol Neurosurg Psychiatry 64:298-305. 1998
  2. ncbi Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Piteå Dementia Project
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Piteå, Sweden
    Neuroepidemiology 18:144-55. 1999
  3. ncbi Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    Arch Neurol 56:673-80. 1999
  4. ncbi Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    Neurosci Lett 273:5-8. 1999
  5. ncbi Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    Neurology 53:1488-94. 1999
  6. ncbi Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, PO Box 715, SE 941 28 Piteå, Sweden
    Arch Neurol 58:373-9. 2001

Detail Information

Publications6

  1. pmc Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    J Neurol Neurosurg Psychiatry 64:298-305. 1998
    ..The aim was also to study if an increase in CSF-tau is found early in the disease process, and whether CSF-tau changes during the progression of disease...
  2. ncbi Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Piteå Dementia Project
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Piteå, Sweden
    Neuroepidemiology 18:144-55. 1999
    ..This means that annually, approximately 300 persons/100,000 population over the age of 40 need medical attention or social services...
  3. ncbi Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    Arch Neurol 56:673-80. 1999
    ....
  4. ncbi Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    Neurosci Lett 273:5-8. 1999
    ..This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase...
  5. ncbi Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, Sweden
    Neurology 53:1488-94. 1999
    ....
  6. ncbi Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
    N Andreasen
    Department of Rehabilitation, Piteå River Valley Hospital, PO Box 715, SE 941 28 Piteå, Sweden
    Arch Neurol 58:373-9. 2001
    ..To evaluate the diagnostic potential of cerebrospinal fluid (CSF) levels of tau and beta-amyloid protein ending at amino acid 42 (Abeta42) as biomarkers for Alzheimer disease (AD) in clinical practice...